SCHEMBL3762901

SCHEMBL3762901

O=C(CN1CCN(C(=O)c2ccccc2-c2ccccc2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.55
RECQL P46063 1/20 0.55
KDM4E B2RXH2 6/20 0.53
ALDH1A1 P00352 5/20 0.53
MAPT P10636 1/20 0.53
ALOX12 P18054 1/20 0.53
L3MBTL3 Q96JM7 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
LMNA P02545 2/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TP53BP1 Q12888 1/20 0.48
CHRM2 P08172 1/20 0.48
SLC6A7 Q99884 1/20 0.47
POLB P06746 1/20 0.47
PARP1 P09874 1/20 0.46
ACACB O00763 1/20 0.46
ACACA Q13085 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767212 0.84 HTT (0.56) KDM4EALDH1A1L3MBTL3L3MBTL1HTT
SCHEMBL3777456 0.84 KDM4E (0.58) TSHRKDM4EALDH1A1L3MBTL3L3MBTL1
SCHEMBL3773907 0.84 KDM2B (0.53) KDM4EALDH1A1L3MBTL3L3MBTL1TP53BP1
SCHEMBL3770797 0.84 L3MBTL3 (0.50) KDM4EALDH1A1L3MBTL3L3MBTL1HTT
SCHEMBL3773954 0.84 MEN1 (0.62) TSHRKDM4EALDH1A1L3MBTL3L3MBTL1
SCHEMBL3770368 0.83 KDM4E (0.67) KDM4EALDH1A1L3MBTL3L3MBTL1HTT
SCHEMBL3762914 0.83 L3MBTL3 (0.55) KDM4EALDH1A1L3MBTL3L3MBTL1TP53BP1
SCHEMBL3780472 0.82 ALDH1A1 (0.59) TSHRKDM4EALDH1A1L3MBTL3L3MBTL1
SCHEMBL13006616 0.82 CYP2C9 (0.63) TSHRKDM4EALDH1A1LMNAPOLB
SCHEMBL3768880 0.82 ALDH1A1 (0.54) TSHRKDM4EALDH1A1L3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 TSHR 436/4885RECQL 3465/4885KDM4E 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.